全球抗感染药物市场规模：依产品、给药途径、应用、最终用户和地区划分，2024-2031年

抗感染市场评估，2024-2031

伊波拉和疟疾等传染病流行率的上升以及公众意识的提高等因素是推动全球抗感染药物市场成长的一些因素。Verified Market Research分析师预计，到2031年，抗感染药物市场估值将达到1,780.1亿美元，低于2023年1,397.5亿美元的收入。

随着世界人口老化的增加，由于感染性疾病的易感性增加，对抗感染药物等药物的需求迅速增加。需求激增将推动市场从2024年到2031年复合年增长率为2.02%。

抗感染市场定义/概述

抗感染药物是指用于预防、治疗和对抗多种病原体（包括细菌、病毒、真菌和寄生虫）引起的感染的一大类药物和物质。这些药物包括多种药物，包括抗生素、抗病毒药物、抗真菌药物、抗菌药物、疫苗和免疫疗法。抗感染药物的主要作用是抑製或杀死感染性细菌的生长，控製或根除感染，恢復感染者的健康。抗感染药物透过控制感染、预防疫情和减少病原体在社区中的传播，在现代医学和公共卫生中发挥重要作用。

抗感染药物还可以彻底杀死感染微生物。抗感染药包括抗霉菌药、驱虫药、抗疟药、抗结核药、抗病毒药和抗寄生虫药。美国食品药物管理局 (FDA) 已批准多种不同类型的药物，包括用于治疗 HIV-1 感染的 Descovy 和用于治疗成人慢性丙型肝炎病毒 (HCV) 基因型 1 或 4 感染的 Zepaty。

推动抗感染药物市场发展的因素有哪些？

细菌、病毒、真菌和寄生虫感染等传染病在全球范围内不断增加，增加了对抗感染药物的需求。人口增长、都市化、旅行和气候变迁等因素导致传染病的传播，需要有效的治疗来限制传播。抗药性病原体的出现，通常称为抗菌素抗药性（AMR），对全球公共卫生构成重大威胁。目前的治疗方法无法应对细菌、病毒、真菌和寄生虫的抗药性菌株，这增加了对能够克服抗药性机制并对抗多重抗药性感染的新型创新抗感染药物的需求，并正在推动抗感染药物的成长。因此，COVID-19、爱滋病毒/爱滋病等传染病以及登革热和疟疾等媒介传播疾病的出现和重新出现阻碍了有效抗感染药物的开发和供应。

随着治疗和程序变得更加复杂，包括手术、移植和免疫抑制治疗，治疗相关感染 (HAI) 的风险也会增加。因此，抗感染药物在 HAI 的预防和治疗、降低併发症的发生率、改善患者的医疗预后方面发挥着重要作用。公共卫生措施、教育活动和意识计划宣传了疫苗接种、手部卫生和抗生素治疗等感染预防和控制措施的重要性。这些努力正在促进抗生素的使用，作为减轻传染病负担和保护公众健康的综合策略的一部分。

此外，新兴国家可支配收入的增加和政府措施可能会导致医疗保健支出增加，从而导致抗感染药物的需求增加。同样，对药物发现、基因组学、联合治疗和个人化医疗的投资增加，正在导致更有针对性、更有效、副作用更少的抗感染药物的开发。

抗感染市场面临哪些课题？

抗感染市场最重要的课题之一是对抗生素产生抗药性的病原体的出现和传播。抗生素、抗病毒药物、抗真菌药物和抗寄生虫药物的过度使用和过度使用导致了抗药性菌株的出现，儘管迫切需要新的抗感染药物，但现有的治疗方法却使法律效力降低，限制了传染病的治疗。抗生素开发管道相对较小。由于抗生素成本高、开发时间长且商业回报不确定，许多製药公司正在减少对抗生素的投资。结果，新的抗生素和其他抗感染药物无法进入市场，加剧了抗菌素抗药性问题。

新型抗感染药物（尤其是药物）的监管审批过程漫长、复杂且耗费资源。特别是针对多重抗药性病原体和新兴传染病的药物需要经过长期而复杂的努力才能获得批准。监管机构需要大量的临床数据来证明安全性、有效性和药物动力学，特别是在抗菌功效的替代物或生物标记尚未确定的情况下，可能会延迟进入市场。经济因素，包括定价压力、报销实践和市场动态，对开发传染病治疗和商业化的公司提出了课题。仿製药抗生素的低廉价格以及临床开发和监管合规的高昂成本阻碍了製药公司投资新抗生素，尤其是针对特定适应症或小型患者群体的抗生素。

在资源有限的环境中，取得抗感染药物往往受到限制，特别是在卫生基础设施薄弱的低收入和中等收入国家。在其他情况下，诊断和治疗方案可能不足。抗生素成本高昂、卫生服务缺乏以及分销和供应链管理方面的课题进一步阻碍了这些地区获得有效的传染病治疗。

目录

第1章 全球抗感染市场介绍

• 市场概况
• 调查范围
• 先决条件

第 2 章执行摘要

第3章 验证市场研究研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章 全球抗感染药物市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析

第5章 全球抗感染药市场：依产品分类

• 概述
• 抗生素
• 抗霉菌药
• 抗病毒剂
• 抗寄生虫药

第6章 全球抗感染药物市场：依给药途径分类

• 概述
• 口服
• 外用
• 肠外
• 吸入

第7章 全球抗感染药市场：依应用分类

• 概述
• 院内感染 (HAI)
• 性传染感染（STI）
• 社区感染

第8章全球抗感染药物市场：依最终用户分类

• 概述
• 医院和诊所
• 家庭医疗
• 研究机构

第9章 全球抗感染药市场：依地区划分

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第10章全球抗感染市场：竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第11章 公司简介

• Pfizer, Inc.
• Abbott Laboratories
• Gilead Sciences, Inc.
• Denso Corporation
• Bristol-Myers Squibb Co.
• Merck & Co., Inc.
• Bayer Healthcare AG
• AstraZeneca Plc.
• Boehringer Ingelheim
• Novartis AG

第12章附录

• 相关研究

Anti-Infective Agents Market Valuation - 2024-2031

The rising prevalence of infectious diseases such as Ebola and malaria along with other factors such as growing awareness among the commoners are some of the factors that are driving the growth of the global anti-infective agents market. According to the analyst from Verified Market Research, the Anti-infective Agents Market is estimated to reach a valuation of USD 178.01 Billion by 2031 by subjugating the revenue of USD 139.75 Billion in 2023.

As the geriatric population grows globally, the requirement of medications like anti-infective agents spurs due to their higher susceptibility to infections. This surge in demand enables the market to grow at aCAGR of 2.02% from 2024 to 2031.

Anti-Infective Agents Market: Definition/ Overview

Anti-infective agents refer to a broad category of medications or substances used to prevent, treat, or combat infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These agents encompass a diverse range of pharmaceuticals, including antibiotics, antivirals, antifungals, and antiphrastic drugs, as well as vaccines and immunotherapies. Their primary function is to inhibit the growth or kill the infectious organisms, thereby controlling or eradicating the infection and restoring health to the affected individual. Anti-infective agents play a critical role in modern medicine and public health by helping to manage infectious diseases, prevent outbreaks, and reduce the spread of pathogens within communities.

The anti-infective agents can also kill the infectious organism outright. The anti-infective group consists of antifungals, anthelmintics, anthelmintics, antimalarials, antituberculosis agents, antivirals, and antiprotozoals. The Food and Drug Administration (FDA) approved various types of drugs such as Descovy for the treatment of HIV-1 infection and Zepatier that target the chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Anti-Infective Agents Market?

The global increase in infectious diseases, including bacterial, viral, fungal, and parasitic infections, is increasing the demand for anti-infective agents. Factors such as population growth, urbanization, travel, and climate change contribute to the spread of infectious diseases that require effective treatment to control the spread of infection. The emergence of drug-resistant pathogens, commonly known as antimicrobial resistance (AMR), poses a major threat to public health worldwide. As current treatments fail against resistant strains of bacteria, viruses, fungi, and parasites, there is a growing need for new and innovative anti-infective agents that can overcome resistance mechanisms and combat multidrug-resistant infections, thereby, boosting the growth of the anti-infective agents market. Consequently, the emergence and re-emergence of infectious diseases like COVID-19, HIV/AIDS, and vector-borne infections like dengue and malaria necessitate the development and availability of effective anti-infective agents to combat them.

The increasing complexity of medicine and procedures, including surgery, transplantation, and immunosuppressive therapy, increases the risk of treatment-associated infections (HAIs). Thus, anti-infective agents play an important role in preventing and treating HAIs, reducing the incidence of complications, and improving patient outcomes in healthcare. Public health initiatives, educational campaigns, and awareness programs promote the importance of infection prevention and control measures, including vaccination, hand hygiene, and antimicrobial treatment. These efforts promote the use of antimicrobial agents as part of comprehensive strategies to reduce the burden of infectious diseases and protect public health.

Also, growing disposable income and government initiatives in emerging countries are leading to rise in healthcare spending, potentially leading to higher demand for anti-infective agents. Similarly, rise in investment on drug discovery, genomics, combination therapies, and personalized medicine are leading to the development of more targeted and effective anti-infective agents with fewer side effects.

What are the Challenges in Anti-infective Agents Market?

One of the most important challenges in the anti-infective market is the emergence and spread of pathogens resistant to antimicrobials. The excessive use and abuse of antibiotics, antivirals, antifungals, and anti-parasitic contribute to the emergence of drug-resistant strains, making existing treatments less effective and limiting treatment for infectious diseases despite the urgent need for new anti-infective agents, the pharmaceutical. The antimicrobial development pipeline is relatively small. Many pharmaceutical companies have reduced their investments in antimicrobial RandD drugs due to the high costs, long development timelines, and uncertain commercial returns of these therapies. As a result, there are no new antibiotics or other anti-infective agents on the market, exacerbating the problem of antimicrobial resistance.

Regulatory approval processes for new anti-infective agents can be long, complex, and resource intensive, especially for drugs. That targets multidrug-resistant pathogens or emerging infectious diseases. Regulatory agencies require extensive clinical data demonstrating safety, efficacy, and pharmacokinetics, which can delay approval and market entry of new therapies, particularly in the absence of defined surrogates or biomarkers of antimicrobial efficacy. Economic considerations, including pricing pressures, reimbursement practices, and market dynamics, present challenges to companies that develop and commercialize infectious agents. The low prices of generic antibiotics and the high costs of clinical development and regulatory compliance prevent pharmaceutical companies from investing in new antimicrobials, especially those targeting specific indications or small patient populations.

Availability of anti-infectives is often limited in resource-constrained settings, especially in low and middle-income countries with poor health infrastructure. , diagnostic options, and treatment options may be inadequate. The high cost of proprietary antimicrobials, lack of health services, and problems with distribution and supply chain management further impede access to effective infectious disease treatments in these regions.

Category-Wise Acumens

Which Product Segment is Projected to Hold a Major Share in the Market?

The antibacterial segment is anticipated to hold almost 50% share in the anti-infective agents market. This dominance of antibacterial agents is primarily due to their increasing use to treat a broad spectrum of bacterial infections, right from common respiratory infections to life-threatening conditions like pneumonia and sepsis. In the majority of cases, bacterial infections are proven to be a common cause of illnesses, propelling demand for antibacterial agents for prevention and treatment.

Ongoing research and development in the field of antibacterial drug discovery or therapies along with the presence of prominent drug manufacturers developing new antibiotics to treat infections is projected to bolster the sales of antibacterial agents over the coming years. However, the rise of antimicrobial resistance is a growing concern, necessitating the development of novel anti-infective agents across all categories to combat various types of infections.

While the antibacterial segment is estimated to hold a major share of the market, the antiviral segment is anticipated to exhibit rapid growth over the forecast period after the emergence of the COVID-19 pandemic.

Will Demand for Easy Administration Increase Sales of Oral Anti-Infective Agents?

The oral administration is currently holding the leading position in the route of administration segment within the anti-infective agents market during the forecast period. The convenience for administration in patients compared to other routes, including injection or inhalation, is surging demand for oral administration. Also, the need for improved medical adherence and efficient treatment outcomes creates lucrative opportunities for oral medications.

Additionally, the cost-effectiveness is projected to increase its accessibility for patients and healthcare systems.

Besides, the availability of a vast array of anti-infective agents in oral formulations, catering to the treatment of various infections across different patient populations is a market growth booster.

Country/Region-wise Acumens

Which Region has most potential for growth of Anti-infective Agents Market?

Asia-Pacific has a huge and diversified population, resulting in differing degrees of healthcare access and infrastructure. The region has a high incidence of infectious illnesses, such as respiratory infections, diarrheal diseases, vector-borne diseases, and new infectious threats including antimicrobial-resistant infections. Infectious disorders are prevalent in the region, driving the demand for effective anti-infective medications. Many Asia-Pacific countries are experiencing economic growth and development, which is driving up healthcare spending and infrastructure investment. Rising affluence, urbanization, and government measures to promote healthcare access all contribute to increased demand for healthcare services, such as anti-infective medicines. Emerging economies in Asia-Pacific, including China, India, Indonesia, and Vietnam, provide considerable growth potential for pharmaceutical businesses and healthcare services.

This region has antimicrobial resistance (AMR) concerns as a result of extensive antibiotic usage, insufficient infection control measures, and restricted access to healthcare services. Addressing antimicrobial resistance necessitates collaborative efforts to encourage antimicrobial stewardship, surveillance, and research, resulting in an increased need for new and novel anti-infective drugs in the area. Governments in the Asia-Pacific region are launching steps to enhance healthcare systems, increase access to medications, and address public health concerns, especially infectious illnesses. Public-private collaborations, legislative changes, and investment incentives are all helping fund anti-infective agent research and development, promoting innovation and market expansion.

Which Region Dominates in Anti-Infective Agents Market?

North American healthcare systems and infrastructure are among the most sophisticated in the world. The region is home to prominent pharmaceutical businesses, research organizations, and healthcare facilities focused on infectious disease management and treatment. The availability of cutting-edge medical facilities and experience helps to accelerate the research, manufacture, and uptake of anti-infective medications.

North American government is making large investments in pharmaceutical and healthcare research and development (R&D). The presence of prestigious academic institutions, government-funded research organizations, and private-sector R&D facilities accelerated the discovery and development of novel anti-infective agents. The region's powerful R&D environment helps scientists to translate their findings into clinically useful therapies. The regulatory framework in North America, notably in the United States, supports pharmaceutical discovery and commercialization.

Despite its modern healthcare system, North America continues to confront difficulties from infectious illnesses and antibiotic resistance. The region bears a heavy burden of healthcare-associated diseases, community-acquired illnesses, and new infectious threats. Antimicrobial resistance is becoming a major problem, demanding the development of new anti-infective medicines with novel modes of action and increased efficacy. Many of the world's largest pharmaceutical firms conduct research, development, production, and marketing of anti-infective drugs in North America. These firms use their scientific knowledge, financial resources, and worldwide networks to spur innovation and fulfill unmet medical needs in infectious disease treatment. The existence of a robust pharmaceutical industry ecosystem helps North America dominate the anti-infective agents market.

Competitive Landscape

The competitive landscape in the anti-infective agents market is dynamic and evolving, driven by changing customer preferences, technological advancements, and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the anti-infective agents market include:

Pfizer, Inc., Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc., Bayer Healthcare AG, AstraZeneca Plc., Boehringer Ingelheim, Novartis AG, Astellas Pharma, Inc., GlaxoSmithKline Plc., Alcon Pharmaceuticals Ltd.

Latest Developments

In February 2024, a novel antifungal drug developed by Gilead Sciences, Inc. was approved by the FDA to treat an uncommon and potentially fatal fungal infection. Its repertoire of anti-infective medicines is expanded by this approval.

In August 2023, in order to treat respiratory syncytial virus (RSV) infection in newborns, Merck & Co., Inc. recently reported positive Phase 3 trial results for its experimental antiviral medication. There may be a new therapeutic option in this area thanks to this development.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL ANTI-INFECTIVE AGENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4. GLOBAL ANTI-INFECTIVE AGENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.2 Porters Five Force Model
• 4.3 Value Chain Analysis

5. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antibacterial Drugs
• 5.3 Antifungal Drugs
• 5.4 Antiviral Drugs
• 5.5 Antiparasitic

6. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 Overview
• 6.2 Oral
• 6.3 Topical
• 6.4 Parenteral
• 6.5 Inhalation

7. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Hospital Acquired Infections (HAIs)
• 7.3 Sexually Transmitted Infections (STIs)
• 7.4 Community-acquired Infections

8. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY END-USERS

• 8.1 Overview
• 8.2 Hospital & Clinic
• 8.3 Homecare Settings
• 8.4 Research Institutes

9. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10. GLOBAL ANTI-INFECTIVE AGENTS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11. COMPANY PROFILES

• 11.1 Pfizer, Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Abbott Laboratories
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Gilead Sciences, Inc.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Denso Corporation
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Bristol-Myers Squibb Co.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Merck & Co., Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bayer Healthcare AG
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 AstraZeneca Plc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Boehringer Ingelheim
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Novartis AG
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12. Appendix

• 12.1 Related Research